Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Better Buy: CRISPR Therapeutics vs. Bluebird Bio

TheMotleyFool

0 0

Better Buy: CRISPR Therapeutics vs. Bluebird Bio: https://g.foolcdn.com/editorial/images/705730/physicians-in-an-operating-room.jpg

Gene editing refers to techniques that allow researchers to modify the DNA of various organisms. Given that it offers the potential to help discover innovative therapies, it isn't surprising that more and more drugmakers are turning to the technology.

Two prominent biotechs that focus on gene editing are CRISPR Therapeutics (NASDAQ: CRSP) and Bluebird Bio (NASDAQ: BLUE). While both stocks have lagged the market recently, there's substantial upside potential for these innovative biotechs.

But which one is a better long-term investment? Let's dig in and find out.

Source Fool.com

Like: 0

CRSP

Share